
Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the “end of the road” for renal denervation?
Keywords: Ambulatory blood pressure monitoring; baroreceptor activation; interventional management; office blood pressure; renal sympathetic denervation; resistant hypertension